EAN Programme Committee Member, Prof. Joaquim Ferreira, talks about the most significant recent developments with respect to movement disorders and what he considers will be the most exciting/promising developments over the next 2 years. Part 1 of 2.
View Part 2 here.
Speaker disclosures: nothing to disclose in relation to this video interview.
Filmed at the 3rd Congress of the European Academy of Neurology (EAN), Amsterdam, June 2017.
Share this Video
Related Videos In Movement Disorders
World Congress on Controversies in Neurology (CONy): Presidential highlights, Amos D. Korczyn
The 17th World Congress on Controversies in Neurology (CONy) took place March 23-25 2023 in Dubrovnik, Croatia. Prof. Amos D. Korczyn, CONy President (University of Tel-Aviv, Tel-Aviv, Israel) joined touchNEUROLOGY to discuss the main aims and focus of the recent CONy meeting, the unique debate presentation style, and the most exciting debates, topics and highlights […]
Francisco Cardoso: International Parkinson and Movement Disorder Society (MDS) – President update
The International Parkinson and Movement Disorder Society (MDS) is a professional society of clinicians, scientists, and other healthcare professionals, who are interested in Parkinson’s disease, related neurodegenerative and neurodevelopmental disorders, hyperkinetic movement disorders, and abnormalities in muscle tone and motor control. touchNEUROLOGY caught up with the MDS President, Prof. Francisco Cardoso, to discuss the upcoming […]
Donald Gilbert, AAN 2022: Ecopipam investigated for the treatment of children and adolescents with Tourette’s syndrome – Phase 2b results
Ecopipam is an investigational first-in-class drug being evaluated for the treatment of children and adolescents with Tourette’s syndrome. Prof. Donald Gilbert (Cincinnati Children’s Hospital Medical Centre, Cincinnati, OH, USA) discusses the randomised, double-blind, placebo-controlled phase 2b study investigating ecopipam. The abstract entitled ‘Ecopipam in Children and Adolescents with Tourette Syndrome: Results from a Randomized, Double-Blind, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!